Dorota Pawlik1, Ryszard Lauterbach2, Maria Walczak3, Joanna Hurkała1, Michael P Sherman4. 1. Department of Neonatology, Jagiellonian University Medical College, Kraków, Poland. 2. Department of Neonatology, Jagiellonian University Medical College, Kraków, Poland ryszard@lauterbach.pl. 3. Department of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, Kraków, Poland. 4. Division of Neonatology, Department of Child Health, University of Missouri School of Medicine, Columbia, Missouri.
Abstract
BACKGROUND: Preliminary studies suggest that fish-oil lipid emulsion given parenterally to very preterm infants reduces the severity of retinopathy (ROP) and cholestasis. METHODS:Infants weighing <1250 g at birth were randomly allocated to 2 groups: an experimental group of 60 infants that received an intravenous (IV) soybean, olive oil, and fish oil emulsion, and a control group of 70 infants that was given a parenteral soybean and olive oil emulsion. Plasma and erythrocyte concentrations of docosahexaenoic acid (DHA) were determined using a high-performance liquid chromatography-mass spectrometry analysis. RESULTS: Nine infants in the fish oil group required laser therapy for ROP compared with 22 infants in the standard intralipid group (risk ratio [RR], 0.48; 95% confidence interval [CI], 0.24-0.96). Three infants in the fish oil group developed cholestasis compared with 20 infants in the standard intralipid group (RR, 0.18; 95% CI, 0.055-0.56). The mean plasma DHA concentrations in treated infants were 2.9-fold higher in the fish oil group than in control infants on the 7th and 14th days of life. The mean DHA content in erythrocytes of treated infants was 4.5-fold and 2.7-fold higher compared with controls at 7 and 14 days of age. CONCLUSIONS:Premature infants receiving anIV fat emulsion containing fish oil had less ROP requiring laser treatment and less cholestasis than those receiving a standard lipid emulsion. These infants also had higher plasma and erythrocyte DHA levels at 7 and 14 days, suggesting potential long-term neurodevelopmental benefits.
RCT Entities:
BACKGROUND: Preliminary studies suggest that fish-oil lipid emulsion given parenterally to very preterm infants reduces the severity of retinopathy (ROP) and cholestasis. METHODS:Infants weighing <1250 g at birth were randomly allocated to 2 groups: an experimental group of 60 infants that received an intravenous (IV) soybean, olive oil, and fish oil emulsion, and a control group of 70 infants that was given a parenteral soybean and olive oil emulsion. Plasma and erythrocyte concentrations of docosahexaenoic acid (DHA) were determined using a high-performance liquid chromatography-mass spectrometry analysis. RESULTS: Nine infants in the fish oil group required laser therapy for ROP compared with 22 infants in the standard intralipid group (risk ratio [RR], 0.48; 95% confidence interval [CI], 0.24-0.96). Three infants in the fish oil group developed cholestasis compared with 20 infants in the standard intralipid group (RR, 0.18; 95% CI, 0.055-0.56). The mean plasma DHA concentrations in treated infants were 2.9-fold higher in the fish oil group than in control infants on the 7th and 14th days of life. The mean DHA content in erythrocytes of treated infants was 4.5-fold and 2.7-fold higher compared with controls at 7 and 14 days of age. CONCLUSIONS: Premature infants receiving an IV fat emulsion containing fish oil had less ROP requiring laser treatment and less cholestasis than those receiving a standard lipid emulsion. These infants also had higher plasma and erythrocyte DHA levels at 7 and 14 days, suggesting potential long-term neurodevelopmental benefits.
Authors: Zhongjie Fu; Chatarina A Lofqvist; Zhuo Shao; Ye Sun; Jean-Sebastien Joyal; Christian G Hurst; Ricky Z Cui; Lucy P Evans; Katherine Tian; John Paul SanGiovanni; Jing Chen; David Ley; Ingrid Hansen Pupp; Ann Hellstrom; Lois E H Smith Journal: Am J Clin Nutr Date: 2015-02-04 Impact factor: 7.045
Authors: Yan Gong; Zhongjie Fu; Matthew L Edin; Chi-Hsiu Liu; Zhongxiao Wang; Zhuo Shao; Thomas W Fredrick; Nicholas J Saba; Peyton C Morss; Samuel B Burnim; Steven S Meng; Fred B Lih; Kin Sing Stephen Lee; Elizabeth P Moran; John Paul SanGiovanni; Ann Hellström; Bruce D Hammock; Darryl C Zeldin; Lois E H Smith Journal: Arterioscler Thromb Vasc Biol Date: 2016-07-14 Impact factor: 8.311
Authors: Roland N Dickerson; Vanessa J Kumpf; Allison B Blackmer; Angela L Bingham; Anne M Tucker; Joseph V Ybarra; Michael D Kraft; Todd W Canada Journal: Hosp Pharm Date: 2016-07
Authors: Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang Journal: Surv Ophthalmol Date: 2018-04-19 Impact factor: 6.048